Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18–14/KM10B)

We investigated the efficacy and safety of a trastuzumab biosimilar, Herzuma®, in combination with treatment of physician's choice (TPC) in patients with HER2+ metastatic breast cancer (MBC) who had failed at least two HER2 directed chemotherapies.

Detalles Bibliográficos
Autores principales: Sim, Sung Hoon, Kim, Jeong Eun, Kim, Min Hwan, Park, Yeon Hee, Kim, Jee Hyun, Suh, Koung Jin, Koh, Su-Jin, Park, Kyong Hwa, Kang, Myoung Joo, Ahn, Mi Sun, Lee, Kyoung Eun, Kim, Hee-Jun, Ahn, Hee Kyung, Kim, Han Jo, Park, Keon Uk, Byun, Jae Ho, Park, Jin Hyun, Lee, Gyeong-Won, Lee, Keun Seok, Sohn, Joohyuk, Jung, Kyung Hae, Park, In Hae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429798/
https://www.ncbi.nlm.nih.gov/pubmed/36029565
http://dx.doi.org/10.1016/j.breast.2022.08.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429798/
https://www.ncbi.nlm.nih.gov/pubmed/36029565
http://dx.doi.org/10.1016/j.breast.2022.08.002

Ejemplares similares